Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Refractory Behçet's Disease Uveitis
NCT03554161Phase 2Terminated
- Start
- May 2018
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in Behçet's disease (BD). Started May 2018; status: terminated.
02
Drugs
tocilizumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT03554161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554161.